相关实验视频

Updated: Sep 20, 2025

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

用低强度调节治疗状细胞疾病的lentiviral基因疗法:一期1/2试验

Michael Grimley^1,2, Stella M Davies^1,2, Archana Shrestha^2,3

¹Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Nature medicine

|May 26, 2025

概括

使用GbG^M的基因疗法与降低强度的调节为状细胞疾病提供了有前途的治疗方法. 这种方法成功地减少了患者的严重血管闭塞事件,证明了未来试验的安全性和可行性.

科学领域:

血液学血液学血液学
基因治疗基因治疗
细胞疗法细胞疗法

背景情况:

状细胞疾病 (SCD) 治疗传统上涉及肌肉衰变条件,导致显著的毒性.
基因改造自主细胞移植是SCD的新兴治疗策略.
降低强度调节 (RIC) 提供了一种潜在的更安全的替代方案,而不是肌肉衰变调节.

研究的目的:

在SCD患者中评估自主干细胞移植使用病毒载体 (GbG^M) 与RIC的安全性和可行性.
评估GbG^M在产生抗发病的胎儿血红蛋白 (HbF^G16D) 和减少血管封闭事件中的有效性.
在第一次在人身上进行的1/2期研究中确定安全性和可行性的主要终点.

主要方法:

七名SCD患者接受了用GbG^M进行基因改造的自身造血干细胞.
在移植之前使用了低强度调节.
主要终点包括CD34+细胞的收集,成功的转导和1年后的载体拷贝数.
根据不良事件和中性质减退和血小板减退的持续时间来评估安全性.

主要成果:

满足了所有主要可行性终点,包括细胞采集,转导和载体拷贝数.
4级血小板缺血的中位持续时间为5天,4级中性质缺血的中位持续时间为8天.
所有七名患者都显示了持续的HbF^G16D表达和严重的血管封闭事件>80%的减少.
最常见的不良事件是2-3级血管封闭性危机.

结论:

具有RIC的GbG^M修饰细胞的自身移植对于SCD治疗是安全的和可行的.
这种基因治疗方法在减少严重的血管闭塞事件方面显示出显著的潜力.
需要进行更大的临床试验,以进一步评估RIC在SCD基因治疗中的治疗益处.

更多相关视频

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.